Category archives: Biosimilar

Letter from Taj Pharma CEO and Leadership Team COVID-19

Letter from Taj Pharma CEO and Leadership Team COVID-19
At Taj Pharmaceuticals, we are working on using this challenge as an opportunity to make our company more dedicated, more efficient, and more focused on serving the needs of our clients, a better company to partner with in our common mission of bringing healthcare treatments to market faster and of improving outcomes for patients. COVID-19, Taj Pharma?CEO, Generics Supply, COVID-19 trials, COVID-19 treatments Generics Supply Centers, COVID-19 clinical trials, coronavirus ongoing trials

Taj Life Sciences (Taj Pharma Group): Our commitment to clients in the spread of COVID-19

Taj Life Sciences (Taj Pharma Group): Our commitment to clients in the spread of COVID-19
We Taj Pharmaceuticals are in the midst of challenging times, brought upon us due to the unimaginable spread of COVID-19. As we grapple with this difficult and ever evolving situation, we wanted to reach out to make sure that you are doing okay and in case you needed any help. It is hard to think of a business that is not impacted by this pandemic, the effects of which we will all continue to feel for a long time.

Despite lower price of generic imatinib, overall costs for chronic myeloid leukemia remain high

Despite lower price of generic imatinib, overall costs for chronic myeloid leukemia remain high
Despite lower price of generic imatinib, overall costs for chronic myeloid leukemia remain high ORLANDO ? The price of generic imatinib has decreased substantially in the United States over the past 2 years, according to a speaker at ASH Annual Meeting and Exposition. The decline comes after steep increases in...

Another Record Year for Generic Drug Approvals {Taj Life Sciences}: [Generic Competition]

Another Record Year for Generic Drug Approvals {Taj Life Sciences}: [Generic Competition]
Another Record Year for Generic Drug Approvals {Taj Life Sciences}: [Generic Competition] For each of the last five years, the US Food and Drug Administration (FDA) has set generic drug approval records, but questions have lingered on whether these high approval numbers are translating into competition. FY 2019 figures show...

Look back at the decade: Generic drugs

Look back at the decade: Generic drugs
Fifteen years after it rose and went limp, the biotech sector saw a bull run of sorts In 2010, an unusual protest erupted over a still negotiated and secret free trade agreement between India and the European Union. Protesters were people living with HIV/AIDS and cancer. They saw a threat...

WHO signs MOU with International Generic and Biosimilar Medicines Association to promote access

WHO signs MOU with International Generic and Biosimilar Medicines Association to promote access
WHO signs MOU with International Generic and Biosimilar Medicines Association to promote access Full access to medicines is hampered by a variety of factors. Two important barriers are high prices and regulatory issues such as long lag times in bringing medicines to market. To address these issues, Dr Tedros Adhanom...

WHAT IS PHARMA PATENTING: A JUDICIAL APPROACH

WHAT IS PHARMA PATENTING: A JUDICIAL APPROACH
WHAT IS PHARMA PATENTING: A JUDICIAL APPROACH FROM {TAJ PHARMA INDIA} BRAND INFRINGEMENT ?Affluent societies are spending vast sums of money understandably on the search for new products and processes to alleviate suffering and to prolong life. In the process, drug manufactures have become a powerful industry. My idea of...